Lonza appoints new COO for Pharma & Biotech business

Company: Lonza

Marc Funk will take over following departure of Stephan Kutzer

Lonza Group, a Swiss supplier to the pharmaceutical and biotech industries, says Marc Funk will lead its Pharma & Biotech segment as Chief Operating Officer from 1 July.

He will replace Stephan Kutzer, who has announced that he will be leaving Lonza.

Funk has been Lonza's Chief Legal Officer and Board Secretary since 2009 and a member of the Executive Committee since 2012. He has already successfully managed operational and commercial projects in the Pharma & Biotech network and has been responsible for Global Quality in Pharma & Biotech at Lonza for more than a year. He has broad experience in this field as he was formerly co-founder of a biotech research company and has had a strong commercial focus in other parts of his career.

Funk will continue as the Group’s Chief Legal Officer and Board Secretary for a transition period until his successor is announced.

You may also like

Ingredients

Staying ahead of the ADC curve

Even after the first antibody–drug conjugate (ADC) was approved in 2000 — Pfizer’s Mylotarg (gemtuzumab ozogamacin) — it took some time for these products to any make significant impact on the market. Now, though, the numbers have reached double figures, with many more ADC therapeutics currently working their way through the clinical pipeline, reports Charles Johnson, Senior Director, Commercial Development at Lonza Small Molecules
Manufacturing

Lonza to support development of ovarian cancer drug

The CDMO will provide kilogram-scale synthesis, purification, and stability testing for Oasmia’s drug candidate
Manufacturing

Lonza expands stem cell offering for humanised mouse models

Humanised mice are used to explore how novel cancer biotherapies interact with a human-specific immune system
Manufacturing

Lonza to supply prequalified cells for CN Bio OOC technology

Organ-on-a-chip technology has the potential to solve the issues presented by 2D cell cultures and animal models, the companies say
Ingredients

Lonza announces cryopreserved Leukopak offering

Fresh Leukopaks can be hard to access and must be used rapidly to avoid cell degradation, limiting transportation options
Ingredients

Lonza introduces hi-res HLA-typed primary cell lots

This offering builds on the company’s human primary cell capabilities
Ingredients

The Lonza powder-in-capsule microdosing approach

Jeff Williamson and Ben Sahacic explain how microdosing offers a proven approach for biopharmaceutical companies to quickly assess new drug candidates while minimising API consumption
Subscribe now